Preclinical Murine Models for Lung Cancer: Clinical Trial Applications

被引:112
作者
Kellar, Amelia [1 ]
Egan, Cay [1 ]
Morris, Don [1 ]
机构
[1] Univ Calgary, Dept Med Oncol, Calgary, AB T2N 4N2, Canada
关键词
SMALL-CELL LUNG; EPIDERMAL-GROWTH-FACTOR; PHASE-II TRIAL; POSITRON-EMISSION-TOMOGRAPHY; TYROSINE KINASE INHIBITOR; IN-VIVO; ANTITUMOR-ACTIVITY; MOUSE MODELS; TUMOR-GROWTH; T-ANTIGEN;
D O I
10.1155/2015/621324
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Murine models for the study of lung cancer have historically been the backbone of preliminary preclinical data to support early human clinical trials. However, the availability of multiple experimental systems leads to debate concerning which model, if any, is best suited for a particular therapeutic strategy. It is imperative that these models accurately predict clinical benefit of therapy. This review provides an overview of the current murine models used to study lung cancer and the advantages and limitations of each model, as well as a retrospective evaluation of the uses of each model with respect to accuracy in predicting clinical benefit of therapy. A better understanding of murine models and their uses, as well as their limitations may aid future research concerning the development and implementation of new targeted therapies and chemotherapeutic agents for lung cancer.
引用
收藏
页数:17
相关论文
共 122 条
[1]  
Abrams TJ, 2003, MOL CANCER THER, V2, P1011
[2]   Grape Seed Proanthocyanidins Inhibit the Growth of Human Non-Small Cell Lung Cancer Xenografts by Targeting Insulin-Like Growth Factor Binding Protein-3, Tumor Cell Proliferation, and Angiogenic Factors (Publication with Expression of Concern. See vol. 24, pg. 6101, 2018) [J].
Akhtar, Suhail ;
Meeran, Syed M. ;
Katiyar, Nandan ;
Katiyar, Santosh K. .
CLINICAL CANCER RESEARCH, 2009, 15 (03) :821-831
[3]  
Belinsky SA, 2003, CANCER RES, V63, P7089
[4]   Phase II, Multicenter, Uncontrolled Trial of Single-Agent Sorafenib in Patients With Relapsed or Refractory, Advanced Non-Small-Cell Lung Cancer [J].
Blumenschein, George R., Jr. ;
Gatzemeier, Ulrich ;
Fossella, Frank ;
Stewart, David J. ;
Cupit, Lisa ;
Cihon, Frank ;
O'Leary, James ;
Reck, Martin .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (26) :4274-4280
[5]  
BOS JL, 1989, CANCER RES, V49, P4682
[6]   EXPRESSION OF C-MYC IN PROGENITOR CELLS OF THE BRONCHOPULMONARY EPITHELIUM AND IN A LARGE NUMBER OF NONSMALL CELL LUNG CANCERS [J].
BROERS, JLV ;
VIALLET, J ;
JENSEN, SM ;
PASS, H ;
TRAVIS, WD ;
MINNA, JD ;
LINNOILA, RI .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1993, 9 (01) :33-43
[7]   Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma [J].
Carter, Christopher A. ;
Chen, Charles ;
Brink, Cheryl ;
Vincent, Patrick ;
Maxuitenko, Yulia Y. ;
Gilbert, Karen S. ;
Waud, William R. ;
Zhang, Xiaomei .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 59 (02) :183-195
[8]   A model of pulmonary adenocarcinoma in transgenic mice expressing the simian virus 40 T antigen driven by the rat Calbindin-D9K (CaBP9K) promoter [J].
Chailley-Heu, B ;
Rambaud, C ;
Barlier-Mur, AM ;
Galateau-Salle, F ;
Perret, C ;
Capron, F ;
Lacaze-Masmonteil, T .
JOURNAL OF PATHOLOGY, 2001, 195 (04) :482-489
[9]   p53 Status is a major determinant of effects of decreasing peroxiredoxin I expression on tumor growth and response of lung cancer cells to treatment [J].
Chen, Miao-Fen ;
Chen, Wen-Cheng ;
Wu, Chun-Te ;
Lin, Paul-Yang ;
Shau, Hungyi ;
Liao, Shuen-Kuei ;
Yang, Cheng-Ta ;
Lee, Kuan-Der .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (05) :1461-1472
[10]   Multiple pulmonary adenomas in the lung of transgenic mice overexpressing the RON receptor tyrosine kinase [J].
Chen, YQ ;
Zhou, YQ ;
Fu, LH ;
Wang, D ;
Wang, MH .
CARCINOGENESIS, 2002, 23 (11) :1811-1819